Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Surgical Science Sweden AB is a leading developer and provider of virtual reality training simulations for medical professionals. The company's primary function is to offer advanced solutions that enhance the training of surgeons and medical staff, effectively using technology to improve patient care outcomes. Surgical Science Sweden's virtual reality platforms are highly regarded in the medical simulation sector, offering lifelike experiences that help users hone their skills without the risk associated with real-life surgeries. The company's role in the medical field is pivotal, as it addresses the growing need for efficient, effective, and safe surgical training. Headquartered in Sweden, Surgical Science Sweden AB collaborates with medical institutions, universities, and healthcare providers worldwide. Its platforms support a range of medical specializations, including laparoscopy, endoscopy, and ultrasound, making it a versatile player in the market. By bridging technology and medicine, Surgical Science Sweden AB is instrumental in driving innovation within the healthcare and medical education sectors, ensuring that practitioners maintain high standards of practice through continuous learning and simulation-based training.
kr 32.40
+kr 0.96 (+3.05%)
Live · 05:17 PM · Twelve Data
Operating margin is thin at 6.94%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 12.2%, still solid. Margins contracted 9.4pp, which offsets some of the top-line progress.
At 31x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 66% versus the prior year, cash generation momentum has weakened.
31.5x earnings, 17.7x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 977M
▲ +12.2% YoY
Net Income (TTM)
kr 52M
▼ -49.2% YoY
Op. Margin
6.95%
▼ -9.4pp YoY
ROIC
1.00%
▼ -1.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 93M
▼ -66.0% YoY
Op. Cash Flow (TTM)
kr 115M
▼ -56.0% YoY
Net Debt
-kr 558M
Net Cash Position
Cash & Equiv.
kr 616M
3Y CAGR: +7.3%
3Y CAGR: -31.5%
Continue Research
At a P/E of 31.5 and a price-to-free-cash-flow of 17.7, Surgical Science Sweden AB (SUS.XSTO) trades below a two-stage DCF intrinsic value of about SEK 103.39 per share, so at SEK 32.40 the stock looks undervalued (219.1% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Surgical Science Sweden AB scores 44/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 103.39 per share for SUS.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 77.54. At today's SEK 32.40, that puts the stock about 219.1% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Surgical Science Sweden AB scores 44 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 6.9% operating margin and a 1.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. SUS.XSTO currently trades below its estimated intrinsic value and scores 44/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.